#884: How to Spot 10-Year Trends and Build Billion-Dollar Companies — Kevin Ryan of DoubleClick, MongoDB, Business Insider, and Many More

What It Covers

Kevin Ryan — founder of MongoDB, Business Insider, Gilt Group, and Transcend Therapeutics — explains his framework for identifying 10-year trends, building companies from scratch at Alicorp, recruiting early talent, and why his second fund targets deep tech, healthcare, and AI at the earliest possible stages.

Key Questions Answered

• •10-Year Trend Framework: Write 20 trends on a whiteboard, then ask two questions: will this market grow 5x over a decade, and what products will exist that don't exist today? Most people complete step one but skip step two. Ryan missed founding YouTube by failing to model the second-order implication that bandwidth costs dropping below $1 per thousand would make video advertising viable by 2005.
• •Business Crush Test: Validate startup ideas by tracking whether you cannot stop thinking about them for two full weeks. If the idea keeps building in your mind — adding people, features, and use cases spontaneously — proceed without a formal business model. Ryan argues that projecting user numbers for a new category is impossible anyway; product quality is the only variable worth modeling in year one.
• •Start Narrow, Then Stack Verticals: Launch with one product serving one audience, execute it well, then add verticals sequentially. Gilt began with one women's clothing sale per week before adding men's, kids, travel, and home. Business Insider launched covering only New York tech with three journalists, then added Wall Street, defense, and retail, eventually reaching 100 million monthly uniques and 600 journalists without ever running a marketing campaign.
• •Moat Dependency in Trend-Based Businesses: Gilt reached $500 million in annual revenue by year four but lost its position when brands like Marc Jacobs built direct e-commerce sites and department stores improved their own platforms. The lesson: trend-based businesses require a defensible moat — supplier exclusivity, scale advantages, or switching costs — large enough that competitors cannot replicate your position once the market matures around you.
• •Second Mouse Gets the Cheese: Entering a category after early movers have made visible mistakes is a deliberate strategy. Transcend Therapeutics studied why earlier psychedelic drug companies failed FDA review — primarily duration-of-action problems and bundled psychotherapy that regulators could not standardize — then selected methylone specifically because its shorter duration fits standard clinical scheduling and weekly dosing is tolerable, unlike MDMA which depletes serotonin with repeated use.
• •Fund Size Discipline: Alicorp's first fund runs at roughly 60% IRR by staying small — approximately 23 employees — and focusing exclusively on the first five years of company building rather than accumulating assets. Ryan deliberately avoids raising a large fund because the 2% management fee model incentivizes asset growth over returns. Selling roughly one-third of positions in rounds four or five years in provides liquidity without abandoning high-conviction holdings prematurely.